Mode
Text Size
Log in / Sign up
N/A Completed N=1,095

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Source: ClinicalTrials.gov NCT00904215 ↗
Enrolled (actual)
1,095
Serious AEs
—
Results posted
Aug 2009
Primary outcomePrimary: Change in SBP (Systolic Blood Pressure) — -18 mmHg — p=<0.0001

Summary

An observational study to investigate the efficacy, safety, tolerability and the effect on quality of life of Telmisartan (Micardis) and Telmisartan with HCTZ (Micardis Plus) in patients with hypertension

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in SBP (Systolic Blood Pressure)
-18 <0.0001 sig
PRIMARY
Change in DBP (Diastolic Blood Pressure)
-10 <0.0001 sig
PRIMARY
Change in WHO-QOL (WHO-Quality Of Life)
2.5 <0.0001 sig
SECONDARY
Change in VAS (Visual Analog Scale)
5.9 <0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Ability to provide written/verbal informed consent in accordance with GCP (Good Clinical Practice) and local legislation
  • Patients aged 18 ~ under 80
  • Hypertension as described below:
  • Newly diagnosed patients with hypertension
  • Patients with current antihypertensive therapy

Exclusion Criteria

  • Female subjects who are breastfeeding, pregnant or who plan to be pregnant during the study
  • Known or suspected secondary hypertension(e.g. pheochromocytoma)
  • Patients who have been treated with telmisartan prior to the acquisition of informed consent (including verbal informed consent)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00904215). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search